Total Payments
$1,971
2024 Payments
$416.21
Companies
3
Transactions
23
Medicare Patients
787
Medicare Billing
$176,795
Payment Breakdown by Category
Food & Beverage$1,940 (98.4%)
Education$30.89 (1.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,940 | 21 | 98.4% |
| Education | $30.89 | 2 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,282 | 15 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $423.94 | 5 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $264.87 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $416.21 | 5 | E.R. Squibb & Sons, L.L.C. ($264.87) |
| 2023 | $288.39 | 3 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($288.39) |
| 2022 | $576.30 | 6 | Sunovion Pharmaceuticals Inc. ($343.94) |
| 2021 | $67.20 | 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($67.20) |
| 2019 | $188.11 | 2 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($188.11) |
| 2018 | $179.27 | 2 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($179.27) |
| 2017 | $255.75 | 4 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($175.75) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Education | In-kind items and services | $27.27 | General |
| Category: Psychiatry/Psychology | ||||||
| 10/17/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $140.74 | General |
| Category: Psychiatry/Psychology | ||||||
| 04/25/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REJOYN (Device) | Food and Beverage | In-kind items and services | $86.22 | General |
| Category: PSYCHIATRY | ||||||
| 04/17/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $96.86 | General |
| Category: Psychiatry/Psychology | ||||||
| 01/10/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $65.12 | General |
| Category: PSYCHIATRY | ||||||
| 09/27/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $115.46 | General |
| Category: PSYCHIATRY | ||||||
| 05/23/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $71.06 | General |
| 04/26/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $101.87 | General |
| Category: PSYCHIATRY | ||||||
| 12/15/2022 | Sunovion Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $125.47 | General |
| 11/08/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $83.14 | General |
| Category: PSYCHIATRY | ||||||
| 07/28/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $103.24 | General |
| Category: PSYCHIATRY | ||||||
| 07/13/2022 | Sunovion Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $94.74 | General |
| 03/25/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $45.98 | General |
| Category: PSYCHIATRY | ||||||
| 03/24/2022 | Sunovion Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $123.73 | General |
| 04/28/2021 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $67.20 | General |
| Category: PSYCHIATRY | ||||||
| 10/01/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $98.28 | General |
| Category: PSYCHIATRY | ||||||
| 04/30/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $89.83 | General |
| Category: PSYCHIATRY | ||||||
| 08/21/2018 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $99.32 | General |
| Category: PSYCHIATRY | ||||||
| 05/06/2018 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $79.95 | General |
| Category: PSYCHIATRY | ||||||
| 12/14/2017 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $77.00 | General |
| Category: PSYCHIATRY | ||||||
| 06/01/2017 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $98.75 | General |
| Category: PSYCHIATRY | ||||||
| 05/05/2017 | Sunovion Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $76.38 | General |
| 04/11/2017 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Education | In-kind items and services | $3.62 | General |
| Category: CNS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 173 | 515 | $349,900 | $46,278 |
| 2022 | 3 | 189 | 595 | $389,946 | $50,851 |
| 2021 | 4 | 225 | 599 | $354,306 | $49,780 |
| 2020 | 4 | 200 | 452 | $168,868 | $29,887 |
Total Patients
787
Total Services
2,161
Medicare Billing
$176,795
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 109 | 328 | $281,424 | $33,880 | 12.0% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 39 | 152 | $42,560 | $8,581 | 20.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 18 | $17,280 | $2,745 | 15.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 17 | $8,636 | $1,072 | 12.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 119 | 373 | $320,034 | $37,974 | 11.9% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 46 | 188 | $52,640 | $10,843 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 24 | 34 | $17,272 | $2,034 | 11.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 100 | 287 | $246,246 | $30,632 | 12.4% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 44 | 182 | $50,960 | $10,695 | 21.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 65 | 103 | $52,324 | $6,241 | 11.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 16 | 27 | $4,776 | $2,212 | 46.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 88 | 208 | $84,448 | $12,137 | 14.4% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 42 | 115 | $32,200 | $6,522 | 20.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 41 | 77 | $43,890 | $6,461 | 14.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 29 | 52 | $8,330 | $4,767 | 57.2% |
About Dr. Michael Gitlin, M.D
Dr. Michael Gitlin, M.D is a Psychiatry healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821018086.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Gitlin, M.D has received a total of $1,971 in payments from pharmaceutical and medical device companies, with $416.21 received in 2024. These payments were reported across 23 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($1,940).
As a Medicare-enrolled provider, Gitlin has provided services to 787 Medicare beneficiaries, totaling 2,161 services with total Medicare billing of $176,795. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Los Angeles, CA
- Active Since 07/20/2006
- Last Updated 07/16/2024
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1821018086
Products in Payments
- REXULTI (Drug) $1,125
- COBENFY (Drug) $264.87
- REJOYN (Device) $86.22
- LATUDA (Drug) $3.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Los Angeles
Dr. Walter Ling, Md, MD
Psychiatry — Payments: $397,562
Psychiatry $397,562
Dr. Jakub Juros, Md, MD
Psychiatry — Payments: $363,152
Psychiatry $363,152
Lon Schneider, Md, MD
Psychiatry — Payments: $270,419
Psychiatry $270,419
John Brooks, M.d, M.D
Psychiatry — Payments: $134,275
Psychiatry $134,275
Stephen Marder, Md, MD
Psychiatry — Payments: $119,068
Psychiatry $119,068
Alexander Bystritsky
Psychiatry — Payments: $55,320
Psychiatry $55,320